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Abstract Taxane-based chemotherapy for the treatment
of breast cancer is associated with fluid retention in the
extremities; however, its association with development of
breast cancer-related lymphedema is unclear. We sought to
determine if adjuvant taxane-based chemotherapy in-
creased risk of lymphedema or mild swelling of the upper
extremity. 1121 patients with unilateral breast cancer were
prospectively screened for lymphedema with perometer
measurements. Lymphedema was defined as a relative
volume change (RVC) of C10 % from preoperative base-
line. Mild swelling was defined as RVC 5-\10 %.
Clinicopathologic characteristics were obtained via medi-
cal record review. Kaplan–Meier and Cox proportional
hazard analyses were performed to determine lymphedema
rates and risk factors. 29 % (324/1121) of patients were
treated with adjuvant taxane-based chemotherapy. The
2-year cumulative incidence of lymphedema in the overall
cohort was 5.27 %. By multivariate analysis, axillary
lymph node dissection (ALND) (p\ 0.0001), higher body
mass index (p = 0.0007), and older age at surgery
(p = 0.04) were significantly associated with increased
risk of lymphedema; however, taxane chemotherapy was
not significant when compared to no chemotherapy and
non-taxane chemotherapy (HR 1.14, p = 0.62; HR 1.56,
p = 0.40, respectively). Chemotherapy with docetaxel was
significantly associated with mild swelling on multivariate
analysis in comparison to both no chemotherapy and non-
taxane chemotherapy groups (HR 1.63, p = 0.0098; HR
2.15, p = 0.02, respectively). Patients who receive taxane-
based chemotherapy are not at an increased risk of lym-
phedema compared to patients receiving no chemotherapy
or non-taxane adjuvant chemotherapy. Those treated with
docetaxel may experience mild swelling, but this does not
translate into subsequent lymphedema.
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Introduction
As the survival from early breast cancer continues to im-
prove, the effects of post-treatment-related complications
on long-term quality of life (QOL) have become increas-
ingly important. Women treated for breast cancer face a
lifetime risk of developing lymphedema, which is a chronic
swelling of the arms, breast, or trunk due to an accumulation
of lymphatic fluid in the interstitial tissues along with tissue
remodeling and increased fibrosis. This condition is one of
the most feared side effects of breast cancer treatment and is
known to have a profoundly negative impact on QOL [1–6].
According to a recent meta-analysis, approximately one in
five survivors will develop lymphedema [7].
Axillary lymph node dissection (ALND), regional
lymph node radiation (RLNR), and higher body mass index
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(BMI) at time of diagnosis are well-established risk factors
for development of lymphedema [1, 3, 8–20]. Some studies
have reported increased incidence of lymphedema after
chemotherapy [1, 7, 8, 13, 21–27]; however, other studies
have not supported these findings [12, 28–30].These results
warrant further investigation regarding the relationship
between adjuvant chemotherapy and lymphedema.
Taxane-based chemotherapy is routinely used in the
treatment of high-risk breast cancer and has been shown to
improve both disease-free survival and overall survival.
[31–35]. A common side effect of taxane-based che-
motherapy, specifically docetaxel, is increased extracellu-
lar fluid (ECF) which often presents as fluid retention in the
extremities [36–39]. Patients typically receive premedica-
tion with corticosteroids to prevent or delay onset of tax-
ane-induced fluid retention while receiving treatment [36,
40]. However, it is unclear if taxane chemotherapy causes
long-term arm swelling after completion of treatment.
Little data exists regarding the association between
taxane-based chemotherapy and lymphedema development
in breast cancer survivors. To date, only three studies have
examined this relationship and all report that taxane-based
chemotherapy increases the risk of lymphedema [41–43].
However, these studies are limited by lack of pre-operative
arm volume measurement, varying definitions of lym-
phedema, small sample size, and limited long-term follow-
up.
Since generalized fluid retention is common following
taxane chemotherapy, we postulated that adjuvant taxane-
based chemotherapy may overwhelm the compromised
lymphatic vessels from breast and/or axillary surgery and
therefore increase risk of lymphedema. We sought to de-
termine whether taxane-based chemotherapy for the treat-
ment of breast cancer is associated with increased risk of
lymphedema in a large cohort of patients prospectively
screened for arm volume changes. Additionally, we sought
to investigate the relationship between taxane-based che-
motherapy with mild arm swelling versus chronic arm
swelling, and determine if type of taxane (paclitaxel vs.
docetaxel) affected lymphedema risk.
Materials and methods
Study design
Per standard of care at our institution, all newly diagnosed
breast cancer patients undergo routine screening for lym-
phedema with serial perometer arm volume measurements.
The perometer is an optoelectronic device that uses in-
frared beams to measure and calculate overall limb volume
[44–46]. Bilateral arm volume measurements are obtained
pre-operatively, post-operatively, after completion of
chemotherapy and/or radiation, and at regular follow-up
oncology visits. This screening protocol was approved by
the Partners Healthcare Institutional Review Board and has
been previously published [47] [Clinicaltrials.gov Identi-
fication number NCT01521741].
Patient population
We identified 1121 women diagnosed with unilateral breast
cancer between 2005 and 2012 who underwent surgery and
prospective screening for lymphedema at our institution.
All patients had a baseline arm volume measurement
and C18 months of post-operative follow-up. Clinico-
pathologic characteristics, patient demographics, and
treatment data were collected via medical record review.
Arm measurements obtained after bilateral breast surgery
or diagnosis of metastasis were excluded.
Lymphedema definition and measurement
Arm volume was quantified using the previously validated
relative volume change (RVC) equation, which calculates
change in volume compared to a pre-operative measure-
ment [47]. Briefly, RVC = [(A(2)U(1)/U(2)A(1)) - 1],
where A(1), A(2) are the preoperative (1) and postoperative
(2) arm volumes on the surgical side and U(1), U(2) are
arm volumes on the contralateral side at corresponding
time points. The RVC equation accounts for asymmetry
between the arms prior to surgery and utilizes the con-
tralateral arm as a control to account for factors unrelated
to lymphedema that may cause change in arm size such as
weight gain or loss. Lymphedema was defined as a C 10 %
RVC occurring[3 months post-operatively. This defini-
tion was based on the scientific consensus in the literature
which commonly utilizes a C 10 % increase in the affected
limb as criteria for diagnosing lymphedema [7, 12, 48, 49].
For the present study, we also investigated the risk of
mild swelling as defined by RVC C 5 to\10 %.
Chemotherapy
Taxane-based chemotherapy was classified as regimens
containing docetaxel (Taxotere), paclitaxel (Taxol), or al-
bumin-bound paclitaxel (Abraxane). Dexamethasone
premedication was administered per institutional standard
for each regimen. Patients who received neoadjuvant che-
motherapy were excluded from this analysis.
Statistical analysis
Patient characteristics were summarized and compared
between patients who did and did not receive taxane-based
chemotherapy via Chi square and Wilcoxon tests. Two-
394 Breast Cancer Res Treat (2015) 151:393–403
123
year cumulative incidence of lymphedema, defined as
RVC C 10 % measured at least 3 months after surgery,
was calculated within each taxane group using the Kaplan–
Meier method. Median time from surgery to onset of
lymphedema was calculated among patients who devel-
oped lymphedema. Univariate and multivariate Cox pro-
portional hazard models were used to evaluate the
association between lymphedema risk and use of taxane-
based chemotherapy, as well as other risk factors. Time-
dependent covariates were included for use of systemic
therapies and radiation fields such that cases were included
in the unexposed group prior to initiation of a given
treatment and then were included in the exposed group
after treatment began. The effects of treatment with pa-
clitaxel and docetaxel were evaluated both combined (i.e.
receiving either agent versus neither) and separately (pa-
clitaxel versus docetaxel versus no taxane treatment).
Multivariate models were derived using backwards selec-
tion, starting with a model that included all variables that
were significant (p\ 0.1) in the univariate analysis, and
removing non-significant variables one at a time until only
significant variables (p\ 0.05) remained. Two-way inter-
actions were evaluated for all covariates included in the
resulting model. An additional analysis was conducted to
assess the relationship between taxane use and risk of low
level swelling, defined as 5 % B RVC\ 10 % measured
at least 3 months after surgery. Patients with RVC C 10 %
were excluded from this analysis.
Results
Patient population
Arm volume measurements from 1121 patients were in-
cluded with a median post-operative follow-up of
39.7 months (range 7.7–103.3). All patients underwent
unilateral breast surgery with 76 % (854/1121) lumpec-
tomy and 24 % (267/1121) mastectomy. 66 % (738/
1121) underwent sentinel lymph node biopsy (SLNB)
and 20 % (219/1121) had axillary lymph node dissection
(ALND). 14 % (164/1121) did not have any nodal sur-
gery, largely due to diagnosis of ductal carcinoma in situ.
Of the 219 patients treated with ALND, 73 % (159/219)
subsequently received taxane chemotherapy compared to
7 % (16/219) treated with non-taxane chemotherapy and
20 % (44/219) did not receive adjuvant chemotherapy.
Out of 738 patients who had SLNB, 22 % (165/738)
received taxane chemotherapy, 6 % (46/738) received
non-taxane chemotherapy, and 71 % (527/738) received
no chemotherapy. Clinicopathologic factors of patients
with and without taxane-based chemotherapy are listed in
Table 1.
29 % (324/1121) of the cohort received adjuvant taxane
chemotherapy, 6 % (62/1121) received non-taxane che-
motherapy, and the remaining 66 % (735/1121) received
no chemotherapy. Out of the 324 patients who received
taxane-based chemotherapy, 56 % (181/324) were treated
with paclitaxel, 40 % (131/324) with docetaxel, and 3 %
(9/324) with albumin-bound paclitaxel. 3 patients received
a combination of the above types of taxane-containing
regimens due to intolerance of initial taxane administered.
Cumulative incidence of lymphedema
The two-year cumulative incidence of lymphedema was
5.27 % (95 % CI 4.10–6.76 %) for the overall cohort. By
chemotherapy group, the cumulative incidence of lym-
phedema was 10.29 % (95 % CI 7.43–14.18 %) for those
receiving taxane chemotherapy compared to 4.87 % (95 %
CI 1.60–14.33) for those receiving non-taxane che-
motherapy and 3.07 % (95 % CI 2.03–4.63 %) for those
who did not receiving chemotherapy (Table 2).
Cumulative incidence of mild swelling
The two-year cumulative incidence of mild swelling was
16.37 % for the overall cohort. For patients receiving tax-
ane chemotherapy, the cumulative incidence of mild swel-
ling was 22.76 % (95 % CI 18.19–28.28 %) compared to
7.05 % (95 % CI 2.71–17.71 %) for the non-taxane che-
motherapy group and 14.64 % (95 % CI 12.20–17.53 %)
for those who did not receive any chemotherapy (Table 3).
Timing of swelling
Among patients who developed lymphedema, median time
from final surgery to onset of lymphedema was
19.97 months in the no chemotherapy group, 20.72 months
in the non-taxane chemotherapy group, and 19.41 months
in the taxane chemotherapy group. Among those who de-
veloped mild swelling, median time from final surgery to
onset of mild swelling was 19.28 months in the no che-
motherapy group, 44.21 months in the non-taxane che-
motherapy group and 14.54 months in the taxane
chemotherapy group (Fig. 1).
Univariate analysis
By univariate analysis, adjuvant taxane-based chemother-
apy was associated with a significantly increased risk of
lymphedema, as defined by RVC C 10 %, compared to no
chemotherapy (HR 2.61, p\ 0.0001) as well as non-taxane
chemotherapy (HR 2.90, p = 0.0412). In addition, an
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analysis of paclitaxel and docetaxel as individual agents
showed that both were significantly associated with lym-
phedma risk compared to those who did not receive
chemotherapy (HR 2.00, p = 0.0053; HR 2.54, p = 0.0004,
respectively). However, when compared to the non-taxane
chemotherapy group, only docetaxel was significant for
Table 1 Clinicopathologic characteristics of study population (n = 1121), adjuvant taxane patients (n = 324) compared with patients who









Median age at surgery (months) 57 53 (24–78) 59 (30–89) \0.0001
Median pre-operative body mass index (BMI)b (kg/m2) 26.3 26.6 (16.8–50.4) 26.2 (16.5–55.7) 0.75
Median post-operative follow up (months) 39.7 42.0 (18–100.4) 38.5 (7.7–103.3) 0.05
Breast surgery \0.0001
Lumpectomy 854 (76 %) 207 (64 %) 647 (81 %)
Mastectomy 267 (24 %) 117 (36 %) 150 (19 %)
Axillary surgery \0.0001
None 164 (14 %) 0 (0 %) 164 (21 %)
Sentinel lymph node biopsy (SLNB) 738 (66 %) 165 (51 %) 573 (72 %)
Axillary lymph node dissection (ALND) 219 (20 %) 159 (49 %) 60 (8 %)
Tumor type \0.0001
Invasive Carcinoma 925 (83 %) 320 (99 %) 605 (76 %)
Ductal Carcinoma in Situ (DCIS) 196 (17 %) 4 (1 %) 192 (24 %)
Pathologic characteristics
Median invasive tumor size, cm 1.4 (0.05–12.5) 1.9 (0.2–12.5) 1.1 (0.05–10.5) \0.0001
Median number lymph nodes dissected 2 (0–43) 6 (1–43) 1 (0–26) \0.0001
Median number positive lymph nodes 0 (0–39) 1 (0–39) 0 (0–26) \0.0001
Radiation therapy \0.0001
None 216 (19 %) 40 (12 %) 176 (22 %)
Partial Breast Irradiation (PBI) 96 (9 %) 1 (0.3 %) 95 (12 %)
Breast ? Chest Wall only 640 (57 %) 148 (46 %) 492 (62 %)
Breast ? Chest Wall ? Nodal Radiation (RLNR) 167 (15 %) 133 (41 %) 34 (4 %)
Adjuvant chemotherapy \0.0001
Yes 386 (34 %) 324 (100 %) 62 (8 %)
No 735 (66 %) 0 (0 %) 735 (92 %)
Adjuvant hormonal therapy 0.20
Yes 874 (78 %) 79 (24 %) 167 (21 %)
No 246 (22 %) 244 (76 %) 630 (79 %)
Herceptin-based chemotherapy \0.0001
Yes 87 (8 %) 75 (23 %) 12 (2 %)
No 1031 (92 %) 248 (77 %) 783 (98 %)
a P value for test of association between characteristic and receipt of taxane
b 17 values missing for BMI
Table 2 Two-year cumulative
incidence of lymphedema
(RVC C 10 %) overall and by
chemotherapy group
N 2-Year cumulative incidence (%) 95 % Confidence interval
Entire cohort 1121 5.27 4.10–6.76
No chemotherapy 735 3.07 2.03–4.63
Non-taxane chemotherapy 62 4.87 1.60–14.33
Taxane-based chemotherapy 324 10.29 7.43–14.18
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increased lymphedema risk (HR 3.12, p = 0.0392). Other
significant risk factors included: higher pre-operative BMI,
ALND, greater number of lymph nodes (LNs) removed,
invasive versus ductal carcinoma in situ pathology, greater
number of positive LNs, and RLNR (Table 4).
Univariate analysis of mild swelling, as defined by
RVC C 5 % to\10 %. indicated that taxane chemotherapy
was associated with a borderline significant increase in risk
of mild swelling compared to no chemotherapy (HR 1.31,
p = 0.0512), and a significant increase in risk of mild
swelling compared to non-taxane chemotherapy (HR 1.86,
p = 0.0398). Additionally, comparison of paclitaxel and
docetaxel as individual agents showed docetaxel, but not
paclitaxel to be significantly associated with mild swelling
when compared to non-taxane chemotherapy (HR 2.31,
p = 0.0107; HR 1.65, p = 0.1163, respectively). Docetaxel
was also associated with a significant increase in risk for
mild swelling compared to no chemotherapy (HR 1.62,
p = 0.0084), however, paclitaxel was not (HR 1.16,
p = 0.3882). Other significant risk factors for mild swelling
included older age at surgery, ALND, greater number of LNs
removed, and greater number of positive LNs (Table 5).
Multivariate analysis
Receipt of taxane-based chemotherapy did not remain
significantly associated with increased risk of lymphedema
compared to no chemotherapy (HR 1.14, p = 0.6188) and
non-taxane chemotherapy (HR 1.56, p = 0.3988) on
multivariate analysis. Neither paclitaxel nor docetaxel was
significantly associated with increased lymphedema risk
when analyzed as individual agents (Table 4). Risk factors
that were associated with lymphedema included ALND
(HR 8.19, p\ 0.0001), higher pre-operative BMI (HR
1.05, p = 0.0007), and older age at surgery (HR 1.02,
p = 0.0433) (Table 4).
Adjuvant taxane-based chemotherapy associated with a
borderline increase in risk of mild swelling compared to no
chemotherapy (HR 1.33, p = 0.0778) and non-taxane che-
motherapy (HR 1.74, p = 0.0732). Docetaxel was sig-
nificantly associated with increased risk of mild swelling
when compared to no chemotherapy (HR 1.63, p = 0.0098)
as well as to non-taxane chemotherapy (HR 2.15,
p = 0.0195). Paclitaxel, however, was not associated with
risk of mild swelling in comparison to either the no che-
motherapy group or the non-taxane chemotherapy group
(HR 1.13, p = 0.5428; HR 1.49, p = 0.2174, respectively)
(Table 5). Older age at surgery (HR 1.02, p = 0.0003) and
ALND (HR 1.47, p = 0.0266) were also significantly as-
sociated with increased risk of mild swelling on multivariate
analysis.
Discussion
In this cohort of 1121 patients prospectively screened for
lymphedema with perometer measurements, adjuvant tax-
ane-based chemotherapy with either paclitaxel or docetaxel
was not significantly associated with an increased risk of
lymphedema (RVC C 10 %) compared to no adjuvant
chemotherapy as well as non-taxane chemotherapy. How-
ever, adjuvant chemotherapy with docetaxel was a sig-
nificant risk factor for mild arm swelling (5 to\10 % RVC)
compared to no chemotherapy as well as non-taxane che-
motherapy (p = 0.0098, p = 0.0195, respectively). Addi-
tional risk factors for mild arm swelling were older age at
surgery and ALND. Consistent with the literature, ALND,
pre-operative BMI C 30, and older age at surgery were in-
dependent risk factors for lymphedema (RVC C 10 %).
Currently, taxane-based chemotherapy is administered
for node-positive and high-risk node-negative breast can-
cer, as it has been shown to significantly reduce mortality
[31–35, 38, 50–53]. The use of anthracycline-alone
Table 3 Two-year cumulative
incidence of mild swelling
(RVC 5-\ 10 % RVC) overall





Entire cohort 1121 16.37 14.22–18.80
No chemotherapy 735 14.64 12.20–17.53
Non-taxane chemotherapy 62 7.05 2.71–17.71




0 5 10 15 20 25 30
Median time** from final surgery to onset of lymphedema (months)
No chemotherapy Non-taxane chemotherapy
Taxane-based chemotherapy
** Medians reported among patients who developed lymphedema  
Fig. 1 Median time to onset of lymphedema (RVC C 10 %) by
chemotherapy group
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regimens in breast cancer treatment has declined [54],
which has resulted in a growing increase of taxane-based
chemotherapy for early stage breast cancer. Therefore, a
full understanding of the QOL and long-term implications
of taxanes is necessary.
Docetaxel has relatively greater hematologic toxicity
and is more commonly associated with edema than pacli-
taxel [53]. To reduce incidence and severity of edema,
coticosteroids are routinely administered [40]. Due to
similarities between the mechanism of fluid retention and
development of breast cancer-related lymphedema [55, 56]
the association between taxane-based chemotherapy
(specifically docetaxel) and lymphedema warrants further
investigation. A recent review comparing adjuvant che-
motherapy with and without docetaxel in breast cancer
patients showed that patients receiving docetaxel consis-
tently had increased rates of edema compared to patients
receiving docetaxel-free chemotherapy [57]. This review
Table 4 Univariate and multivariate analysis of characteristics associated with risk of lymphedema (RVC C 10 %)
Univariate results Multivariate resultsc
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
Patient characteristics
Age at surgery (years)a 1.02 (1.00–1.03) 0.1080 1.02 (1.00–1.04) 0.0433
Pre-operative BMIa (kg/m2) 1.07 (1.04–1.10) \0.0001 1.05 (1.02–1.09) 0.0007
Surgical characteristics
Axillary surgery
SLNB versus no axillary surgery 0.83 (0.36–1.89) 0.6507 b –
ALND versus no axillary surgery 6.31 (2.88–13.80) \0.0001 7.32 (3.16–17.01) \0.0001
ALND versus SLNB/no axillary surgery 7.37 (4.86–11.19) \0.0001 8.19 (5.12–13.10) <0.0001
Pathologic characteristics
Invasive vs. DCIS 2.20 (1.06–4.53) 0.0335 1.05 (0.49–2.25) 0.9041
Number positive lymph nodesa 1.10 (1.07–1.13) \0.0001 1.02 (0.98–1.06) 0.4337
Systemic therapy
Adjuvant taxane-based chemotherapy
Yes versus no chemo 2.61 (1.73–3.95) \0.0001 1.14 (0.69–1.87) 0.6188
Yes versus non-taxane chemo 2.90 (1.04–8.08) 0.0412 1.56 (0.56–4.37) 0.3988
Paclitaxel
Yes versus no chemo 2.00 (1.23–3.24) 0.0053 0.81 (0.46–1.41) 0.4473
Yes versus non-taxane chemo 2.45 (0.85–7.07) 0.0984 1.26 (0.43–3.65) 0.6725
Docetaxel
Yes versus no chemo 2.54 (1.52–4.26) 0.0004 1.25 (0.71–2.18) 0.4374
Yes versus non-taxane chemo 3.12 (1.06–9.20) 0.0392 1.95 (0.65–5.85) 0.2334
Non-taxane chemotherapy
Yes versus no chemo 0.90 (0.32–2.52) 0.8417 0.64 (0.22–1.83) 0.4056
Hormonal therapy
Yes versus no 1.59 (0.90–2.80) 0.1098 –
Herceptin-based chemotherapy
Yes versus no 1.10 (0.55–2.20) 0.7778 – –
Radiation therapy
Yes versus no 1.06 (0.65–1.75) 0.8056 – –
RLNR versus breast?chest wall/none 4.32 (2.82–6.63) \0.0001 1.29 (0.77– 2.16) 0.3354
CI confidence interval, BMI body mass index, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, DCIS ductal carcinoma
in situ, RLNR regional lymph node radiation
a Age at surgery, pre-operative BMI, and number of positive lymph nodes were analyzed as continuous variables such that the hazard ratios
reflect the change in lymphedema risk associated with a 1-unit increase in the variable
b ‘‘–’’ indicates the specified variable/comparison was not analyzed
c 2 Separate models, each including age at surgery, BMI and ALND were used to estimate the hazard ratios for (1) adjuvant taxane-based chemo
and (2) individual effects of paclitaxel and docetaxel
398 Breast Cancer Res Treat (2015) 151:393–403
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included studies comparing generalized edema in docetaxel
and docetaxel-free groups, but did not specifically report on
lymphedema of the arm. The relationship between
docetaxel and upper extremity lymphedema is unclear, as
the only studies in the literature examining this are case
reports [58, 59].
The association of breast cancer-related lymphedema
with taxane-based chemotherapy has been reported, but not
widely studied. In 2013, Kilbreath et al. analyzed 160
women for lymphedema with bioimpedence spectroscopy
(BIS) as part of a larger randomized study which evaluated
effect of exercise after breast surgery. Measurements were
taken at 1, 3, 9, and 15 months post-operatively and lym-
phedema was defined according to previously established
cutoffs. On multivariate analysis, patients who received
taxane chemotherapy had a 7-fold greater risk of swelling
in the arm at 9-months after surgery compared to women
who did not receive taxane chemotherapy (HR 7.4,
Table 5 Univariate and multivariate analysis of characteristics associated with risk of mild swelling (5 B 10 % RVC)
Univariate results Multivariate resultsc
Hazard Ratio (95 % CI) p value Hazard Ratio (95 % CI) p value
Patient characteristics
Age at surgery (years)a 1.02 (1.01–1.03) 0.0011 1.02 (1.01–1.03) 0.0003
Pre-operative BMIa (kg/m2) 1.02 (1.00–1.04) 0.1366 1.01 (0.99–1.03) 0.4157
Surgical characteristics
Axillary surgery
SLNB versus no axillary surgery 0.90 (0.63–1.29) 0.5631 –b –
ALND versus no axillary surgery 1.36 (0.89–2.07) 0.1527 1.35 (0.84–2.18) 0.2188
ALND versus SLNB/no axillary surgery 1.48 (1.10–2.00) 0.0105 1.47 (1.05–2.07) 0.0266
Pathologic characteristics
Invasive vs. DCIS 1.42 (0.99–2.04) 0.0572 1.27 (0.87–1.84) 0.2152
Number positive lymph nodesa 1.07 (1.03–1.11) 0.0002 1.04 (0.99–1.00) 0.0603
Systemic therapy
Adjuvant taxane-based chemo
Yes versus no chemo 1.31 (1.00–1.71) 0.0512 1.33 (0.97–1.83) 0.0778
Yes versus non-taxane chemo 1.86 (1.03–3.35) 0.0398 1.74 (0.95–3.13) 0.0732
Paclitaxel
Yes versus no-chemo 1.16 (0.83–1.62) 0.3882 1.13 (0.77–1.66) 0.5428
Yes versus non-taxane chemo 1.65 (0.88–3.07) 0.1163 1.49 (0.79–2.80) 0.2174
Docetaxel
Yes versus no-chemo 1.62 (1.13–2.32) 0.0084 1.63 (1.13–2.36) 0.0098
Yes versus non-taxane chemo 2.31 (1.21–4.38) 0.0107 2.15 (1.13–4.09) 0.0195
Non-taxane chemotherapy
Yes versus no chemo 0.70 (0.40, 1.24) 0.2265 0.75 (0.42–1.35) 0.3473
Hormonal therapy
Yes versus no 1.05 (0.78–1.41) 0.7639 – –
Herceptin-based chemotherapy
Yes versus no 0.80 (0.50–1.30) 0.3644 – –
Radiation therapy
Yes versus no 1.04 (0.77–1.40) 0.8106 – –
RLNR versus breast ? chest wall/none 1.18 (0.80–1.74) 0.4043 0.82 (0.51–1.31) 0.4064
CI confidence interval, BMI body mass index, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, DCIS ductal carcinoma
in situ, RLNR regional lymph node radiation
a Age at surgery, pre-operative BMI, and number of positive lymph nodes were analyzed as continuous variables such that the hazard ratios
reflect the change in lymphedema risk associated with a 1-unit increase in the variable
b ‘‘–’’ indicates the specified variable/comparison was not analyzed
c 2 Separate models, each including age at surgery, BMI and ALND were used to estimate the hazard ratios for (1) adjuvant taxane-based chemo
and (2) individual effects of paclitaxel and docetaxel
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123
p\ 0.001) [42]. However, taxane chemotherapy did not
remain significant at 15 months post-operative, leading to
the conclusion that taxanes cause transient swelling in the
at-risk arm.
A similar study by Jung et al. evaluating patients who
underwent ALND showed that taxane-based chemotherapy
was an independent risk factor for lymphedema on multi-
variate analysis [41]. In 848 patients evaluated post-op-
eratively for a one-time lymphedema event as well as for
persistent lymphedema, taxane-based chemotherapy was
associated with higher incidence of lymphedema
(HR = 1.69, p = 0.03 for lymphedema event; HR 2.07,
p = 0.04 for persistent lymphedema) [41]. However, pa-
tients did not undergo a pre-operative arm measurement and
lymphedema was defined using a wide range of both objec-
tive and subjective criteria. Interestingly, in our analysis,
taxane-based chemotherapy was not associated with in-
creased risk of lymphedema. Possible explanations for this
include low cumulative incidence of lymphedema of the
entire cohort and the impact of multivariable analysis ad-
justed for factors known to increase risk of lymphedema such
as ALND (Table 3).
Most recently, Lee et al. reported on lymphedema fol-
lowing taxane chemotherapy in women with early stage
breast cancer. 63 patients were assessed with BIS after ax-
illary surgery, before taxane-chemotherapy, and 6 months
after completion of chemotherapy. Results showed that
taxane chemotherapy increased incidence of lymphedema of
the ipsilateral arm and persisted for at least 6 months after
completion of chemotherapy, whereas generalized edema in
the legs resolved during this timeframe [43]. This series was
limited by small sample size and lack of long-term follow-
up. In our series the median time to lymphedema in all co-
horts was between 19 and 21 months post-surgery, therefore
the increased swelling that this study reports could be related
to transient edema.
The results of our study show adjuvant docetaxel in-
creases risk of mild swelling; however, multivariate analysis
indicates that this does not subsequently lead to increased
risk of lymphedema. These findings are consistent with the
reported side effects of docetaxel treatment, and further the
understanding of the relationship between docetaxel and
breast cancer-related lymphedema. More importantly, be-
cause docetaxel is not an independent risk factor for lym-
phedema and the median time to onset of lymphedema was
similar across chemotherapy groups (Fig. 1), results of this
study suggest that it is largely ALND that elevates risk of
lymphedema, not receipt of taxane chemotherapy.
As many patients who receive ALND are also subse-
quently treated with taxanes due to more advanced disease,
these individuals should still be closely monitored for de-
velopment of lymphedema. The strong association between
adjuvant docetaxel and mild swelling highlights the need to
distinguish between minor increases in arm volume versus
chronic lymphedema. Because of our prospective screening
and quantified method of measuring arm volume, the re-
sults of this study fill a gap in the literature regarding risk
of lymphedema after receiving taxane-based chemother-
apy. Furthermore, our data better informs clinicians of
docetaxel-related arm edema, and can help educate patients
on treatment-related risk factors for lymphedema.
Due to the non-randomized selection of patients for
taxane-based chemotherapy versus non-taxane-based che-
motherapy, there are limitations in the present study. At our
institution, few patients receive chemotherapy without a
taxane (i.e. anthracycline alone); out of 1121 patients
eligible for this analysis, only 62 received adjuvant non-
taxane chemotherapy (5.5 %). Although a larger percent-
age of patients receiving non-taxane-based chemotherapy
would have allowed for a more accurate analysis on the
effects of taxane, the minimal usage of anthracyclines
alone in our cohort reflects standard practice and guidelines
for systemic treatment. The nature of our screening pro-
tocol calls for arm volume assessments to be taken before
and after completion of chemotherapy, but not during;
therefore, the data that are reported in this study does not
include any arm volume changes that occurred while re-
ceiving active taxane chemotherapy. Taking these factors
into account, there are many areas for future research.
The current study also has several strengths.We utilized a
large cohort of patients prospectively screened for changes in
arm volume with a perometer, a device with demonstrated
validity for lymphedema assessment [44, 45, 60, 61]. This
cohort of 1121 patients represents one of the largest in the
lymphedema literature, and to our knowledge, the largest in
which risk of lymphedema was evaluated for association
with adjuvant taxane-based chemotherapy. Of note, patients
receiving neoadjuvant chemotherapy were excluded in order
to solely assess the hypothesis that fluid retention from
chemotherapy may overwhelm compromised lymphatic
vessels after surgery, and could therefore lead to chronic
lymphedema. All patients in our study underwent a pre-op-
erative arm volumemeasurement and regular post-operative
screening, with a median follow-up of over 3 years. The
importance of obtaining pre-operative assessments to ac-
count for asymmetry between arms and adjustment for fac-
tors unrelated to lymphedema has been previously
demonstrated [47, 62, 63]. In addition, we utilized a
validated formula to measure arm volume differences, ac-
counting for baseline pre-operative differences as well as
weight changes [64]. Lymphedema was defined as C10 %
RVC,which has beenwidely used in the literature [7, 12, 48].
Our study also separates paclitaxel and docetaxel for risk
of lymphedema due to the well known differences in adverse
events related to these therapeutic agents. Additionally,
distinction between mild and chronic edema was evaluated
400 Breast Cancer Res Treat (2015) 151:393–403
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in both univariate and multivariate models. Mild swelling
was defined as RVC C 5 to\10 % based on our previously
published analysis of 1173 patients in which we found that a
measurement of C5 to\10 % RVC at[3 months post-op-
erative was significantly associated with an increased risk of
progression to C10 % [65]. As the importance of detecting
sublinical edema has been cited in the literature [63, 66–68],
we sought to determine if patients receiving taxane-based
chemotherapy were more likely to exhibit these low level
arm volume increases compared to patients who did not re-
ceive taxane-based chemotherapy. Further, we sought to
determine if mild swelling after taxane chemotherapy led to
progressive lymphedema or if it was transient (never pro-
gressing to RVC C 10 %). Results of our analyses suggest
that docetaxel, but not paclitaxel is associated with risk of
mild swelling, but that neither taxane is a risk factor for
development of lymphedema.
Conclusions
In conclusion, multivariate analysis of 1121 patients
prospectively screened for lymphedema via perometry
demonstrated that taxane-based chemotherapy did not in-
crease risk of lymphedema. Athough docetaxel was found
to be a significant risk factor for mild swelling, it did not
correlate with progressive lymphedema. These findings can
be utilized for patient counseling and education regarding
common side effects while undergoing taxane-based che-
motherapy. Although arm volume changes should be
regularly monitored for early signs of progression, it is
important for clinicians to differentiate between treatment-
related risk factors for developing chronic edema versus
mild or transient edema that may resolve without inter-
vention. This may help patients avoid costly treatment
expenses and potentially reduce fear of lymphedema.
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